The Massachusetts Life Sciences Center

Transcription

1 The Massachusetts Life Sciences Center Confindustria / Biomedical Delegation to Boston November 2013 Investing in the State of Innovation

2 Creating a High- Performance Innovation Ecosystem: The Massachusetts Life Sciences Initiative 2

3 The Massachusetts Life Sciences Center: Who We Are and What We Do The Massachusetts Life Sciences Center develops and offers creative programs that fund innovation-driven economic development initiatives in the Massachusetts life sciences cluster, but also may have relevance for other innovation sectors. Mission: Serve as the hub of the Massachusetts life sciences Supercluster Encourage innovation through investments in good science and good business Strengthen and protect Massachusetts global leadership position in the life sciences Accelerate the commercialization of promising treatments, therapies and cures Create jobs and drive economic development 3

4 The MLSC Invests to Close Gaps Across the Innovation Life Cycle... Discovery Development Delivery The MLSC Strategy: Reduce barriers, fill gaps and promote collaboration across the life sciences innovation process Fund translational research Invest in early-stage companies (pipeline and external innovation) Support workforce development and training Build capacity, infrastructure and unique resources in Massachusetts Partner with and leverage private sector stakeholders Promote and fund convening and collaboration 4

5 MLSC Has a Variety of Investment Tools 10 Years $1 Billion Investment 5

6 The MLSC is a Public-Private Partnership, Governed by a Multi- Disciplinary Board of Directors*. Secretary of Housing and Economic Development Gregory Bialecki Secretary of Administration and Finance Glen Shor President of University of Massachusetts System Robert Caret, Ph.D. A researcher involved in the commercialization of biotechnology, pharmaceuticals or medical diagnostic products Lydia Villa-Komaroff, Ph.D., Director and CSO, Cytonome/ST A physician licensed to practice medicine in the Commonwealth and affiliated with an academic medical center Edward Benz, M.D., President & CEO, Dana-Farber Cancer Institute A person with financial expertise in the life sciences Joshua Boger, Ph.D., Founder & CEO (Retired), Vertex 6 *as of October 2013

7 .and Advised by a Blue Ribbon Scientific Advisory Board* CHAIR: Harvey Lodish, Ph.D., Whitehead Institute and Massachusetts Institute of Technology (MIT) Academia Industry Venture Capital Entrepreneurs James J. Collins, Ph.D., Boston University John M. Collins, Ph.D., Center for Integration of Medicine & Innovative Technology (CIMIT) Robert D Amato, M.D., Ph.D., Center for Macular Degeneration Research, Harvard Medical School and Boston Children s Hospital Rainer Fuchs, Ph.D., Harvard Medical School Glenn R. Gaudette, Ph.D., Worcester Polytechnic Institute (WPI) Judith Lieberman, Ph.D., Immune Disease Institute, Boston Children s Hospital and Harvard Medical School Lita L. Nelsen, Massachusetts Institute of Technology Barbara Osborne, Ph.D., UMass Amherst Guillermo Tearney, M.D., Ph.D., Harvard Medical School, Harvard-MIT Division of Health Sciences and Technology (HST) and Massachusetts General Hospital David Walt, Ph.D., Tufts University School of Medicine Philip Zamore, Ph.D., UMass Medical School James Barry, Ph.D., Arsenal Medical Dalia Cohen, Ph.D., ALN Associates José-Carlos Gutiérrez-Ramos, Ph.D., Pfizer Dale Larson, Draper Laboratory Alan Smith, Ph.D., CBE, FRS, Genzyme (Retired) Kevin Bitterman, Ph.D., Polaris Venture Partners T. (Teo) Dagi, M.D., M.B.A., HLM Venture Partners Jonathan Fleming, M.P.A., Oxford Bioscience Partners Henry Kay, Boston Harbor Angels Carmichael Roberts, Ph.D., M.B.A., North Bridge Venture Partners Lauren Silverman, Ph.D., Novartis Option Fund Alison Taunton- Rigby, Ph.D., RiboNovix, Inc. 7 *as of October 2013

8 There Is Much Evidence of the MLSC s Impact to Date Engagement by the life sciences community Unprecedented participation from industry, and the academic, medical, entrepreneurial and venture communities Leverage Halfway through the 10-year initiative, the MLSC has invested nearly $500M but leveraged $1.2B of matching investments Job creation Life sciences are now fastest job-creating sectors in the state MA is creating new life sciences jobs faster than any other state 10 of 10 All 10 of the top 10 global biopharma leaders are present in MA National recognition National award for excellence in innovation and technologydriven economic development 8

9 The MLSC s Public-Private Partnership Model is Producing High Leverage Public Dollars Invested/Committed = $468 M (June 2008-Sept 2013) Matching Investments Attracted = (June 2008-Sept 2013) Grants to Academic Organizations and Medical Centers Grants for Shovel Ready Capital Projects Investments in Life Sciences Companies 9

10 The MLSC s Public-Private Partnership Model is Producing High Leverage Public Dollars Invested/Committed = $468 M (June 2008-Sept 2013) Matching Investments Attracted = $1.2 B (June 2008-Sept 2013) 10

11 More and More Companies Are Creating a Footprint in the Massachusetts Life Sciences Community:

12 Percent Growth Employment in Life Sciences Indexed to 2001, Massachusetts vs. Big Competitor States Year Sources: B. Bluestone and A. Clayton-Matthews, Life Sciences Innovation as a Catalyst for Economic Development: The Role of the Massachusetts Life Sciences Center (March 2013) 12

13 The Massachusetts Life Sciences Center: Programs and Investments 13

14 MLSC Programs Strengthen the State s World-Class Academic Institutions Objective: Provide matching grants to accelerate the translation of treatments and therapies from the research bench to the bedside Supporting promising scientific research ($14.9 million -- matched dollar for dollar) Funding 21 new investigators ($5.1 million) Helping five universities and academic medical centers compete for top faculty ($3.8 million) Funding research collaborations between 12 industry and academic partners ($6 million) Dr. Jesse Dong (left), Vice President of Compound Discovery and Research at Ipsen Biomeasure, provides a tour of the company s lab facilities to, from left to right, State Senator Richard Moore, Governor Deval Patrick, and State Representative John Fernandes in July

15 The MLSC Internship Challenge Program Increases interest, skill development and employment readiness for life sciences careers by providing real-world experience Funds interns working at Massachusetts companies with fewer than 100 employees Over 1,306 internships placed 145 different colleges and universities represented 356 companies have participated Over $9 million committed to the program to date More than 160 participating interns have been offered full or part-time jobs at the conclusion of their internships 1% 1% 2% 7% 2% 1% 1% 3% 8% 9% Academic Majors of Participating Interns 1% Engineering 31% 33% Biology Chemistry Business Computer Science Neuroscience Pharmaceutical Sciences Physics Regulatory Affairs 15

16 The MLSC Invests to Help Life Sciences Companies Grow Objective: Provide funding and incentives to accelerate the formation and growth of life sciences companies in Massachusetts Business Plan Competitions: Funded $545,000 in sponsorships Accelerator Program: Working capital for early-stage life sciences companies $16.2 million in loans awarded to 25 early-stage companies SBMG Program: Funding to match federal small business grants (SBIR & STTR) $4 million awarded to eight life sciences companies Tax Incentive Program: Incentives for companies to locate and grow jobs in MA MLSC can commit up to $25 million/year 73 active awards totaling $75 million to companies that have created or are promising to create more than 2,800 jobs 16

17 The MLSC Capital Program Bolsters Infrastructure Across the Commonwealth Objective: Expand capital and infrastructure resources available across Massachusetts to support life sciences research, development and commercialization To date the MLSC has committed more than $330M to capital projects across the state Basic infrastructure Cutting-edge research laboratories Unique biomanufacturing resources Incubator spaces UMass Amherst received a $95-million Capital Grant from the MLSC in June 2013 to fit out and equip a substantial portion of the university s new $157-million Life Sciences Laboratories, pictured above. 17

18 Infrastructure Investments --More than $330 million to date Center for Salivary Diagnostics at the Forsyth Institute Children s Center for Cell Therapy at Children s Hospital Emerging Technologies and Innovation Center at UMass Lowell Gateway Park in Worcester Hall of Human Life at Boston s Museum of Science Joint Center for Personalized Cancer Therapy at UMass Boston LabCentral in Kendall Square Loeb Lab at the Marine Biological Laboratory (Renovation) Massachusetts Accelerator for Biomanufacturing (MAB) at UMass Dartmouth Molecular Imaging Cancer Center at Dana-Farber New England Regional Biosafety Laboratory at Tufts Cummings School of Veterinary Medicine Albert Sherman Center at UMass Medical School Systems Pharmacology Lab at Harvard Medical School Translational Center for the Cure of Diabetes at Joslin Wastewater Project at Framingham Technology Park Life Sciences Labratories at UMass Amherst 18

19 The MLSC Facilitates and Funds New Models of Collaboration Objective: Promote new models of collaboration that will accelerate and improve ( innovate ) the innovation process Massachusetts Neuroscience Consortium 19

20 The MLSC Launched a Massachusetts Neuroscience Consortium in June 2012 The Consortium is a pioneering new model of collaboration that leverages Massachusetts rich neuroscience environment Accelerates pre-clinical research available to the pharmaceutical industry Introduces academic researchers to targeted research Facilitates new models of industry-academic partnership Provides sponsors with expedited access to Massachusetts neuroscience cluster the highest density of neuroscience research in the world Neuroscience Consortium Charter members: AbbieVie Merck Biogen-Idec Pfizer EMD Serono Sunovion (DainipponSumitomo) Janssen Research (Johnson and Johnson) 20

21 The MLSC Facilitates and Funds New International Collaboration Objective: Promote collaboration between Massachusetts and the global life sciences community International Partnership Assistance Portal (IP-ap) The MLSC International Collaborative Industry Program Invests in late stage R&D partnerships between a Massachusetts company and an international company partner 21

22 The MLSC International Partnership Assistance Portal (IP-ap) Promotes Collaboration Objective: Facilitate the ability of international and Massachusetts companies to identify and pursue potential partnerships 24/7/365. Free, password-protected, cloud-based portal Open to all MA-based life sciences companies and international life sciences companies Companies provide the qualities they are seeking in a partner Searchable database Create your user profile at es.com 22

23 The MLSC and an International Partner Provide Joint Funding Massachusetts Company Min. 100k Non U.S.-based Company Min. 100k MLSC will match MA company contribution After a min. of $100k/project the rest is determined $ by the agency $ Partner Agency Min. 100k/project, Max. 500k Min. 100k/project 23

24 Keeping in Touch News updates Program information Application portal Life Sciences Center List 4,600 recipients Weekly event listings Sign up today! 24